Halma Regulatory News (HLMA)

Halma plc ('Halma' or the 'Group')

Acquisition

Halma plc, the global group of life-saving technology companies focused on growing a safer, cleaner, healthier future for everyone, every day, today announces that it has acquired itemedical and Naslund Medical for its Healthcare Sector companies SSG and IZI Medical, respectively.

These bolt-on acquisitions strengthen Halma's position in specialist healthcare markets and reflect its disciplined, long-term approach to M&A. Both businesses add complementary capabilities to its companies and support growth in areas with strong long-term drivers, including hospital digitalisation and precision oncology.

itemedical is a Dutch provider of digital platforms that integrates real-time patient data and alarms from different medical devices, supporting clinical decision-making and workflow efficiency in hospitals. The acquisition enhances SSG's digital capabilities and expands its offering in hospital workflow management, supporting growth in a market driven by increasing digitalisation in healthcare systems.

The cash consideration for itemedical is €23m (approximately £20m), on a cash- and debt-free basis, to be funded from Halma's existing facilities. itemedical's unaudited revenue for the 12 months to 31 March 2026 was €7.8m (approximately £7m).

Naslund Medical is a Swedish company specialising in fiducial marker technology used to support targeted cancer treatment. Its core product, Gold Anchor®, enables more precise targeting of tumours during radiation therapy. The acquisition broadens IZI Medical's radiation oncology offering by adding Gold Anchor® to its existing Visicoil platform, supporting customers with a wider range of premium fiducial marker technologies. Naslund also brings an established international footprint, supporting IZI's ambition to expand globally.

The cash consideration for Naslund Medical is $45m (approximately £34m), on a cash- and debt-free basis, to be funded from Halma's existing facilities. Naslund Medical's unaudited revenue for the 12 months to 31 March 2026 was $9.2m (approximately £7m).

Marc Ronchetti, Group Chief Executive of Halma, said: "These acquisitions strengthen our existing companies by adding complementary capabilities in markets they know well, supporting their long-term growth while enabling improved patient outcomes. They operate in areas which have attractive long-term growth drivers and provide a strong platform for continued innovation and international expansion. We are pleased to welcome itemedical and Naslund Medical to Halma."

For further information, please contact:

Halma plc

Marc Ronchetti, Group Chief Executive +44 (0)1494 721111

Carole Cran, Group Chief Financial Officer

Charles King, Co-Head of Investor Relations +44 (0) 7776 685948

Melanie Horton, Co-Head of Investor Relations +44 (0) 7554 013 396

MHP

Oliver Hughes / Rachel Farrington / Ollie Hoare +44 (0)20 3128 8100 / 

+44 (0)7817 458 804

A copy of this announcement, together with other information about Halma, is available at www.halma.com.

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.

Its purpose defines the three broad market areas where it operates:

It employs over 9,000 people in more than 20 countries, with major operations in the UK, Europe, the US and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

Halma has been named as one of Britain's Most Admired Companies for the past seven years.

For more information see www.halma.com